Novartis Reports First RAE346 Phase I/II Data Since Acquisition
Novartis reported Phase I/II data for RAE346 in HR+/HER2- breast cancer, marking the first results since its acquisition.
Novartis reported Phase I/II data for RAE346 in HR+/HER2- breast cancer, marking the first results since its acquisition.